Biomarker Research for Personalized Medicine

NCT01488591 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2013-05-31

No results posted yet for this study

Summary

The aim of this study :

1. Through the study of genes of protein, transporter, translator and epigenome investigating the effect of anti-cancer treatment or the key factor of the MDR (Multidrug resistance) on the blood cancer patients who are under the anti-cancer sork treatment
2. Giving a service of anticancer medicine therapeutic drug monitoring (TDM) and genotyping

Conditions

  • Hematologic Neoplasms

Sponsors & Collaborators

  • Inje University

    lead OTHER

Eligibility

Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2009-04-30

Countries

  • South Korea

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01488591 on ClinicalTrials.gov